RevolutionAir: Philips Launches a Brand-New Wireless SpeechMike Premium Air
Speech Processing Solutions, the world’s number one in professional dictation, has just released its latest innovation, the wireless SpeechMike Premium Air dictation microphone. For the first time in history, the new device offers not only outstanding audio recording quality, enabling exceptional speech recognition results, best in class quality and ergonomics, but also a wireless dictation microphone, based on 100% lossless speech technology. The dictation microphone allows users to quickly turn their voice into text, saving them time and making them more effective at their core profession.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171024005093/en/
Philips SpeechMike Premium Air (Photo: Business Wire)
Lossless speech technology
The high-quality device delivers maximum mobility without any compromises. Dr Thomas Brauner, CEO of Speech Processing Solutions explains: “Our unique new device allows users to benefit from all advantages of the industry leading Philips SpeechMike Premium, without the constraints of a cable”. The new Philips SpeechMike Premium Air uses a unique lossless speech technology, which enables users to work cable-free and without any signal interruptions, up to five meters away from their workstations.
New mobility in dictation
The included docking station provides wireless charging under three hours and instant pairing between the user’s device and the dock. “The charged device can easily be used for up to 24 hours. This is especially useful for heavy users in hospitals, legal practices and other roles which carry a high administrative burden” adds Dr Brauner. Together with a foot control, the SpeechMike Premium Air docking station even enables hands-free recording.
Studio-quality microphone designed for speech recognition
The free-floating decoupled microphone in the SpeechMike Premium Air is equipped with a special noise cancelling “pop filter” and distinctive hexagonal grill openings, which allow three times more sound to reach the microphone, compared to its predecessor. All these unique features guarantee that no background, touch, click, air or structure-borne noise is recorded. This helps users achieve high-quality audio recordings, enabling exceptional speech recognition results.
Easy plug & play including pre-configured button modes
The SpeechMike Premium Air supports plug & play functionality and is fully compatible with previous SpeechMike versions. An office or practice can work seamlessly together, even when employees are using different models. The SpeechMike Premium Air also features pre-configured button modes, catered for the needs of leading speech recognition solutions.
The device also works perfectly with the latest Philips SpeechExec Pro software with integrated professional speech recognition for example, as well as with the Philips’ cloud-based dictation workflow solution SpeechLive. Amongst many of its features, SpeechLive offers a professional transcriptionist service, where trained typists transcribe the recordings as well as built-in speech recognition.
“Once you’ve tried the new SpeechMike Premium Air and experience its uncontested ease of use, outstanding speech recognition performance and have the opportunity to stand up and walk around in your office while recording, you will never want to change back to a corded device! This is the break through our customers and the entire speech industry has been waiting for!” Dr Brauner concludes.
For more information on Philips dictation solutions, please visit: www.philips.com/dictation
About Speech Processing Solutions
Speech Processing Solutions is the global leader in professional dictation solutions. The company was founded in 1954 in Austria as a Philips subsidiary, and has been a driving force for innovative speech-to-text solutions for 60 years. The company developed ground-breaking products such as the mobile Philips SpeechAir, the Philips Pocket Memo voice recorder, the Philips SpeechMike Premium USB dictation microphone and the Philips Dictation Recorder app for smartphones, thus meeting its demands for excellence and superior quality. Thanks to the recent innovation, Philips SpeechLive, dictations and recordings will become faster and easier than ever before with cloud-based workflow services. Speech Processing Solution's perfectly tailored offers and products help professionals save time and resources and maximize efficiency.
Connect with Speech Processing Solutions on:
Twitter @speech_com: http://www.twitter.com/speech_com
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
New data presented at the American Academy of Dermatology show LEO Pharma’s Kyntheum® (brodalumab) improves psoriasis on the nail19.2.2018 09:00 | Tiedote
NOT FOR DISTRIBUTION IN THE UNITED STATES OR UNITED KINGDOM: LEO Pharma today announced new data demonstrating long-term improvements in psoriasis on the nail with Kyntheum® (brodalumab) when compared to placebo or ustekinumab.1 Psoriasis on the nail, which is challenging to treat,2 affects approximately half of the estimated 125 million people living with psoriasis worldwide.2,3 The data were presented at the 76th annual American Academy of Dermatology (AAD) meeting in San Diego, California, US. Psoriasis is a common, chronic, immune-mediated, inflammatory disease that primarily involves the skin, but also impacts emotional, psychological and physical health.4 The heavy and far-reaching burden of the disease can be disabling and stigmatising with a substantial negative impact on those affected and their families.4 Due to the visible nature of the condition, psoriasis on the nail can be particularly upsetting for patients.4 In moderate to severe cases, psoriasis on the nail can be pain
OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers18.2.2018 00:00 | Tiedote
Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im
CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 11:00 | Tiedote
Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates
Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 21:26 | Tiedote
Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a
General Cable Corporation Stockholders Approve Acquisition By Prysmian Group16.2.2018 20:05 | Tiedote
General Cable Corporation (NYSE: BGC) today announced the voting results from the Company’s special meeting of stockholders held this morning. Stockholders of General Cable approved the Company’s previously announced acquisition by Prysmian Group (BIT: PRY) for $30.00 per share in cash. A total of 38,140,754 shares, representing approximately 75.34% of the total number of shares of common stock outstanding and approximately 99% of the total votes cast, were voted in favor of the merger. Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by the third quarter of 2018. About General Cable General Cable (NYSE:BGC), with headquarters in Highland Heights, Kentucky, is a global leader in the development, design, manufacture, marketing and distribution of aluminum, copper and fiber optic wire and cable products for the energy, communications, automotive, industrial, construction and specialty segments. General Cable is one of the larges
Systemic Sclerosis World Congress:Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease16.2.2018 12:03 | Tiedote
Boehringer Ingelheim today unveils a new phase of 'More Than Scleroderma: The Inside Story', and launches the new patient website www.morethanscleroderma.com. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005188/en/ Anna, 36, living with scleroderma (Photo: Business Wire) The global initiative highlights the importance of understanding the ‘inside story’ of each individual living with scleroderma, also known as systemic sclerosis. To coincide with the Systemic Sclerosis World Congress in Bordeaux, 15-17 February 2018, new and truly inspiring patient stories are revealed, reflecting the real-life, diverse and very moving journeys of people living with scleroderma across the world. The campaign will also be launched in the U.S. The new website www.morethanscleroderma.com features a powerful collection of photographs and video stories of people living with scleroderma across the world, revealing the life-changing impact o
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme